Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Barchart on MSN3d
Eli Lilly's Q4 2024 Earnings: What to ExpectEli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback